Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S5 - E3.5 - The New MASLD Nomenclature: What Lies Ahead For MASH Patients And Providers?
This conversation ties up several issues related to MASH and the new MASLD nomenclature that the panel did not touch on earlier in the episode. These range from the impact the nomenclat…
S5 - E3.4 - Discussing MASLD With Patients: MASH Is Not "Just A Little Fat" Any More
This conversation focuses on how the new MASLD nomenclature might improve providers' explanations of MASH to patients. Louise Campbell describes new opportunities, while Meena Bansal de…
S5 - E3.3 - The New MASLD Nomenclature -- MASLD Rollout And Stakeholder Roles
This conversation shifts from the rearview to the path ahead. Louise Campbell starts by asking about the role of Allied Health Providers in the process. After this issue, process leader…
S5 - E3.2 - How Did The Delphi Process Work For The New MASLD Nomenclature?
This conversation focuses on the Delphi process for a new MASLD nomenclature. It starts with Jeff Lazarus describing what a Delphi process is and how it worked here. Jeff and two other …
S5 - E3.1 - Why create a new MASLD nomenclature?
This conversation focuses on the issues and visions that led to the identified need for a new MASLD nomenclature. Maru Rinella and Jeff Lazarus discuss the original goals of the process…
S5 - E3 - The New MASLD Nomenclature And How We Got Here
The process of creating a new MASLD nomenclature for the condition formerly known as Fatty Liver Disease was a multi-year process with unique challenges and complications. Three leaders…
S5 - E2.5 - Conversations From The Vault: Jeff McIntyre On ICER Reviews And NITs
This conversation is part of a March, 2023 interview between co-hosts Louise Campbell and Roger Green and Jeff McIntyre of Global Liver Institute, one of the guests on the S5 E2 panel. …
S5 - E2.4 - MASLD Patient Advocates' Priority 2024 MASH Programs
Leading MASLD patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (NASH kNOWledge) and Wayne Eskridge (Fatty…
S5 - E2.3 - Where Do MASLD Patients And Advocates Fit In MASH Drug Access Decisions?
Leading MASLD patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (NASH kNOWledge) and Wayne Eskridge (Fatty…
S5 - E2.2 - After The First MASH Drug Approval, Focus Shifts To Patient Access
Leading patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (NASH kNOWledge) and Wayne Eskridge (Fatty Liver…
S5 - E2.1 - Expectations For The Resmetirom PDUFA Date - The First MASH Drug Approval?
Leading patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (NASH kNOWledge) and Wayne Eskridge (Fatty Liver…
S5 - E02 - MASLD Patient Advocates Plan MASH Activities For 2024
00:00:00 Surf's Up: Season 5 Episode 2
Co-hosts Louise Campbell and Roger Green sit with four leading MASLD patient advocates (Tony Villiotti of NASH kNOWledge, Wayne Eskridge of the Fa…
S5 - E1.6 - SurfingMASH Is Back! How Can Consumer Behavior Confound MASH Care?
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and access…
S5 -E1.5 - SurfingMASH Is Back! How Will GLP-1 Ads From Telemedicine Affect MASH?
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group examines the explosion of telemarketer-driven consumer advertising for GLP-…
S5 - E1.4 - SurfingMASH Is Back! Reframing "Liver Awareness" In The Context Of US DTC Advertising
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group explores the goal of provider and patient liver education, key goals for li…
S5 - E1.3 - SurfingMASH Is Back! 2024 Podcast Updates And The Increasing Need For "Liver Awareness"
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Louise Campbell describes how VCTE can serve as a behavioral monitor, Roger Green rev…
S5 - E1.2 - SurfingMASH Is Back! Louise Campbell Discusses Building MyLife365.Me And Expanding To New Markets
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Louise Campbell describes her recent efforts in enhancing liver health awareness and …
S5 - E1.1 - SurfingMASH Is Back! Jörn Schattenberg On Becoming Department Director At Saarlands
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Jörn Schattenberg describes the challenges, opportunities and experiences that he has…
S5 - E1 - How might approval of a MASH drug affect patient treatment?
The first episode of Season 5 of Surfing the MASH Tsunami starts with a brief discussion of what the co-hosts have worked on for the last two months and proceeds to consider the impact …
S4 E50.11 - Wrapping Up 2023 - An Interview with Global Liver Institute Vice President, Liver Health Programs, Jeff McIntyre
Surfing the MASH Tsunami continues its 2023 wrap-up conversations with Global Liver Institute Vice President of Liver Health Programs Jeff McIntyre, along with co-hosts Louise Campbell …